BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protein naturally found in human gastric juice. It is widely studied in preclinical research for its role in tissue repair, angiogenesis, and cytoprotective signalling.

How do I reconstitute BPC-157?

Reconstitute with 1-2 ml of bacteriostatic water. Allow the vial to reach room temperature, inject solvent gently down the inside wall, and swirl gently. Never shake. Store reconstituted solution at 2-8°C and use within 4-6 weeks.

What purity is BioLab's BPC-157?

Every batch is independently tested via HPLC and mass spectrometry to confirm 99%+ purity and correct molecular identity. A batch-specific Certificate of Analysis is available with every order.

How should I store BPC-157?

Store lyophilised vials at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 4-6 weeks. Avoid repeated freeze-thaw cycles.

PE-22-28 10 mg

£40.00

PE-22-28 is a synthetic heptapeptide derived from the sortilin propeptide (spadin), studied as a TREK-1 potassium channel inhibitor with neurotrophic and nootropic properties. Available to buy in the UK from BioLab Peptides – 10 mg, 99%+ purity.

Purity: ≥99% (HPLC & MS)
Quantity: 10 mg per vial
Amino Acids: 7 (heptapeptide)
Target: TREK-1 potassium channel
Storage: -20°C (lyophilised) · 2-8°C (reconstituted)

Categories: All Peptides, Cognitive & Nootropic

Description
Reviews (0)

PE-22-28 10 mg – Neurotrophic Research Peptide

PE-22-28 is a synthetic heptapeptide fragment derived from spadin (the sortilin propeptide), originally identified by researchers studying TREK-1 potassium channel modulation. TREK-1 is a two-pore domain potassium channel expressed throughout the CNS that has been implicated in neurogenesis, mood regulation, and neuroprotection.

Research Background

TREK-1 channel inhibition – PE-22-28 acts as a selective inhibitor of the TREK-1 potassium channel. TREK-1 knockout models show enhanced neurogenesis and resistance to depression-like behaviours, suggesting that TREK-1 inhibition promotes neurotrophic signalling.

Neurogenesis – Research indicates PE-22-28 may promote hippocampal neurogenesis by increasing BDNF expression and enhancing neural progenitor cell proliferation, potentially through TREK-1-mediated signalling cascades.

Cognitive research – PE-22-28 has been studied in cognitive performance models, where it has shown effects on learning, memory consolidation, and synaptic plasticity.

Related Products

For complementary nootropic research, see Semax (BDNF upregulation), Selank (anxiolytic nootropic), and P-21 (neurogenesis). Browse Cognitive & Nootropic.

For research use only. Not for human or veterinary consumption.